Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients

Background Most non‐small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase‐tyrosine kinase inhibitor (ALK‐TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK‐TKI therapies; however, little clinical data exi...

Full description

Bibliographic Details
Main Authors: Naoki Haratake, Takashi Seto, Shinkichi Takamori, Ryo Toyozawa, Kaname Nosaki, Naoko Miura, Taro Ohba, Gouji Toyokawa, Kenichi Taguchi, Masafumi Yamaguchi, Mototsugu Shimokawa, Mitsuhiro Takenoyama
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Thoracic Cancer
Subjects:
ALK
non‐small cell lung Cancer
re‐biopsy
resistance
sequential treatment
Online Access:https://doi.org/10.1111/1759-7714.13143

Internet

https://doi.org/10.1111/1759-7714.13143

Similar Items